Teva expands management team
29 April 2013 | By TEVA
Teva appoints Paul J. Sekhri as Group Executive Vice President, Global Business Development and Chief Strategy Officer...
List view / Grid view
29 April 2013 | By TEVA
Teva appoints Paul J. Sekhri as Group Executive Vice President, Global Business Development and Chief Strategy Officer...
23 April 2013 | By TEVA
"We are very pleased to receive orphan drug designation for XEN402..."
8 April 2013 | By Teva Pharmaceutical Industries Ltd.
Teva-Handok announced the appointment of Yoo Suk Hong as the first Chief Executive Officer of the business venture...
8 April 2013 | By Teva Pharmaceutical Industries Ltd
TEVA announced the appointment of Ichiro Kikushige...
3 April 2013 | By GlobalData
India is becoming a key market for generic medicines...
21 March 2013 | By PARADIGM COMMUNICATIONS
TEVA and Active Biotech announced top-line results from the open-label extension of the Phase III ALLEGRO study...
19 February 2013 | By Gilead Sciences
Gilead and Teva Pharmaceuticals have reached an agreement in principle to settle the ongoing patent litigation...
14 February 2013 | By Teva Pharmaceutical Industries Ltd
TEVA announced that the U.S. FDA has approved its Abbreviated New Drug Application (ANDA)...
11 February 2013 | By Teva Pharmaceutical Industries Ltd
Teva announced that Dr. Arie Belldegrun was appointed by the Board of Directors...
16 December 2012 | By Teva Pharmaceutical Industries Ltd
TEVA and Handok announced agreement...
22 October 2012 | By Teva Pharmaceutical Industries Ltd
TEVA and Active Biotech announced the presentation of Phase IIa clinical data...
8 October 2012 | By Teva Pharmaceutical Industries Ltd
Key data from the Company’s MS franchise...
8 August 2012 | By Teva Pharmaceutical Industries Ltd
The clinical trial protocol has been granted a Special Protocol Assessment agreement...
2 August 2012 | By Teva Pharmaceutical Industries Ltd
Dr. Carlo De Notaristefani appointed as President and CEO of Global Operations, and Mr. Aharon (Arik) Yaari as the Executive VP...
14 June 2012 | By Teva Pharmaceutical Industries Ltd
Teva announced positive top-line results from the GALA Phase III clinical trial assessing the efficacy, safety and tolerability...